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Summary
The aim of this study was to elucidate more clearly the role of interleukin
(IL)-18 in modulating the IL-22 pathway in primary Sj€ogren’s syndrome
(pSS) patients and in pSS-associated lymphomas. Minor salivary glands
(MSGs) from patients with pSS and non-specific chronic sialoadenitis
(nSCS), parotid glands biopsies from non-Hodgkin lymphomas (NHL)
developed in pSS patients, were evaluated for IL-18, IL-22, IL-22 receptor
1 (IL-22R1), IL-22 binding protein (IL-22BP) and signal transducer and
activator of transcription-3 (STAT-3) expression. MSGs IL-22R1-
expressing cells were characterized by confocal microscopy and flow
cytometry in pSS, nSCS and healthy controls . The effect of recombinant
IL-18 and IL-22 on peripheral blood mononuclear cells (PBMCs) from
pSS and nSCS was studied by flow cytometry and reverse transcription–
polymerase chain reaction (RT-PCR). MSGs of pSS and NHL were
characterized by an imbalance between IL-22 and IL-22BP protein
expression, with IL-18 and IL-22BP being expressed in a mutually
exclusive manner and IL-18 and IL-22R1 being correlated directly.
Aberrant expression of IL-22R1, induced by IL-18, was observed only
among tissue and circulating myeloid cells of pSS patients and
macrophages of NHL tissues of pSS patients, but not nSCS. IL-22R1
expression on PBMC of pSS was functional, as its stimulation with
recombinant IL-22 significantly up-regulated the expression of STAT-3,
IL-17 and IL-22. An IL-18-dependent aberrant expression of IL-22R1 on
cells of haematopoietic origin seems to be a specific immunological
signature of patients with pSS and pSS-associated lymphomas.
Keywords: IL-18, IL-22, IL-22BP, IL-22R1, non-Hodgkin lymphoma,
Sj€ogren’s syndrome
Introduction
Primary Sj€ogren’s syndrome (pSS) is a chronic systemic
autoimmune disease characterized by dysregulated
immune responses and a higher rate of non-Hodgkin
lymphoma (NHL) risk [1–3].
We have recently shown the occurrence in pSS patients
of a local and systemic over-expression of interleukin
(IL)-18 [4] and IL-22 [5], highlighting the role of dysre-
gulated innate and adaptive immune responses in the
pathogenesis of pSS. Both IL-18 and IL-22 are immune-
stimulatory cytokines participating in the pathogenesis of
chronic inflammatory diseases. IL-22, however, does not
play a role in immune cells cross-talk because, unlike the
IL-10R2 which is expressed constitutively in many human
tissues, IL-22R1 is not detectable in immune cells [6]. In
physiological conditions, in fact, IL-22R1 is expressed on
hepatocytes, keratinocytes, intestinal epithelial cells and
pancreatic cells (reviewed in [7]). In this context, IL-22
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seems to act mainly eliciting proinflammatory responses
to defend rapidly against invading pathogens (reviewed in
[7]). Dysregulation of IL-22 signalling is, however,
described in human inflammatory disorders other than
pSS, such as psoriasis, and in the pathogenesis of solid
tumours of the skin, lung, brain, gastrointestinal tract
and of haematological malignancies (reviewed in [7]).
The final functional outcome of both IL-18 and IL-22
seems to depend upon the levels of the respective binding
proteins [6,8], which are secreted glycoproteins that antag-
onize cytokine activity by specifically blocking their interac-
tion with the cell surface receptors. Recent evidence
indicates that IL-18 can synergize with IL-12 to enhance
IL-22 levels in T helper type 1 (Th1 cells) and also to influ-
ence the IL-22BP in both humans and mice [9,10], suggest-
ing the occurrence of a immunological link between
inflammasome-IL-18 axis and IL-22, and thus between the
early step of innate immunity and the adaptive immunity.
The aim of the present study was to investigate the
relationship between the IL-18 and IL-22 pathway in pSS
and in pSS-associated non-Hodgkin lymphoma.
Materials and methods
Patients and samples
Thirty patients fulfilling the American–European Consen-
sus Group criteria for pSS [11] were enrolled consecutively.
The occurrence of lymphoma was carefully excluded in all
pSS patients by clinical and radiological [sonography, com-
puterized tomography (CT), positron emission tomogra-
phy (PET)/CT] examinations. Fifteen patients also
displaying subjective complaints of dry mouth or eyes who
did not meet the American–European Consensus Group
criteria for pSS were included as non-specific chronic sia-
loadenitis (nSCS) and evaluated as controls. The occurrence
of autoimmune or chronic inflammatory diseases was care-
fully excluded in nSCS subjects. Paraffin-embedded samples
obtained from patients with a previous diagnosis of pSS-
associated lymphoma (n5 10) were selected from the
biopsy bank of the Pathology Unit of the Ospedale Cervello
(Palermo, Italy). Histologically, lymphomas were diagnosed
by the presence of sheets or halos of monocytoid B cells and
the presence of clonal populations was confirmed by poly-
merase chain reaction (PCR) analysis for immunoglobulin
(Ig)H and/or IgL chain restriction. Blood from 10 healthy
subjects (HC) [eight female, mean age6 standard deviation
(s.d.) 436 5!6] was also obtained. Clinical characteristics of
the patients and controls are shown in Table 1. Minor labial
salivary glands (MSG) biopsies from pSS and nSCS
patients, obtained during routine diagnostic procedures,
were placed into formalin fixative, RNA later or RPMI. All
the patients and controls gave their informed consent and
the study was approved by the ethical committee of the
University of Palermo. Paraffin-embedded sections of 5-lm
thickness were stained with haematoxylin and eosin (H&E)
for histological evaluation and MSG were assessed for the
presence of lymphocytic infiltrates and/or foci (defined as
aggregates of" 50 lymphocytes) and the focus score was
reported as the number of foci per 4 mm2 of tissue [12].
RNA isolation and quantitative real-time reverse
transcription–polymerase chain reaction (RT–PCR)
RT–PCR was performed on whole SGs or isolated SG
mononuclear cells (SGMCs), as described previously [5].
Master mix and TaqmanV
R
gene expression assays for glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) control
and target genes were obtained from Applied Biosystems
(Foster City, CA, USA) (Table 2). Final values were
expressed as fold of induction (FOI).
Immunohistochemistry
Immunohistochemistry was performed on 5-lm-thick
paraffin-embedded sections from salivary glands, tonsils







Age (years) (range) 43 (25–60) 54 (33–68) 59 (49–67)
Female sex, n (%) 26 (86) 12 (80) 5 (100)
Disease duration,
months (range)
70 (12–240) 96 (22–300) 103 (60–180)
Anti-nuclear antibodies,
n (% of patients)




18 (60) – 80
Rheumatoid factor
(% of patients)
13 (44) – 80
ESR mm/h, mean (s.d.) 33 (14) 15 (4) 70 (21)
C-reactive protein, mg/l,
mean (s.d.)
11 (3) 4 (1!5) 23 (7)
Low C4 level n (%) 2 (6!6) – 5 (50)
Cryoglubulinaemia n (%) 2 (6!6) – 5 (50)
Focus score 0–1 n (%) 7 (23!3) – –
Focus score 2 n (%) 5 (16!6) – –
Focus score 3 n (%) 7 (16!6) – –
Focus score 4 n (%) 11 (36!6) – –
Germinal centre n (%) 8 (26!6) – –
Extraglandular involvement n (%)
Synovitis 2 (6!6%) – –
Vasculitis 3 (10) – –
Auto-immune cytopaenia 1 (3!3) – –
Cutaneous involvement 5 (16) – –
Renal involvement 2 (6!6) – –
Pulmonary involvement 1 (3!3) – –
Neurological involvement 2 (6!6) – –
*Clinical data of patients with primary Sj€ogren’s syndrome (pSS)
patients who developed non-Hodgkin lymphoma (NHL) are referred
to the time of the onset of lymphoma. nSCS5 non-specific chronic
sialoadenitis.
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(used as positive controls) and from parotids of non-
Hodgkin lymphomas from pSS patients, as described pre-
viously [5]. A list of the primary and secondary antibod-
ies used is provided in Table 2.
Flow cytometry
Minor SGMC and PBMCs were obtained as described pre-
viously [5] from 20 pSS patients and eight nSCS subjects.
PBMCs were also obtained from 10 healthy subjects. For
SGMC isolation, salivary gland tissues were washed in saline
buffer and enzymatic digestion was performed using colla-
genase (1!5 mg/ml; Life Technologies, Carlsbad, CA, USA)
in Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing antibiotics for 2 h. Recovered cells were then cultured
with phorbol myristate acetate (PMA) (50 ng/ml) and iono-
mycin (0!5 mg/ml) and incubated at 378C in 5% CO2. Cell
viability (trypan blue dye exclusion) was always> 95%.
After 2 h of incubation brefeldin A (10 mg/ml; Sigma, St
Louis, MO, USA) was added and after 16 h of incubation
cells were collected and stained with monoclonal antibodies
(mAb). A list of the antibodies used is shown in Table 2.
Four-colour flow cytometry analysis was performed using a
fluorescence activated cell sorter (FACS)Calibur (BD Bio-
sciences, San Jose, CA, USA). At least 50 000 cells (events),
gated on the lymphocytes or monocytes/macrophages
region, were acquired for each sample.
Cell cultures with recombinant IL-22 and IL-18
PBMCs isolated from heparinized blood samples of 10 pSS
and 10 nSCS patients by centrifugation over Ficoll-Hypaque
(Sigma) density gradients and SGMC obtained from five pSS
with focus score 1–2 were cultured in 24 flat-bottomed plates
(Becton Dickinson Labware, Franklin Lakes, NJ, USA) at a
density of 1 3 106 cells in 1 ml of RPMI-1640 medium with
10% fetal calf serum (FCS), 2 mM L-glutamine, 20 nM
HEPES and 100 U/ml penicillin/streptomycin with or without
recombinant IL-22 (rIL-22) (0!1 or 10 ng/ml) (R&D Systems,
Minneapolis, MN, USA) and IL-18 (10 or 20 ng/ml) (MBL
International, Woburn, MA, USA). Cells were incubated at
378C in a humidified atmosphere containing 5% CO2 for
48 h and for 5 days; after incubation cells were characterized
by flow cytometry and reverse transcription–polymerase
chain reaction (RT-PCR) for IL-17, IL-22, IL-23, RAR-related
orphan receptor (ROR)c and signal transducer and activator
of transcription-3 (STAT-3) was also performed.
Statistical analysis
Parametric and non-parametric statistical analysis was
been performed calculating the mean6 standard devia-
tion (s.d.) and median, respectively. For comparison of
parametric and non-parametric data, t-test and Mann–
Whitney rank-sum test were used where appropriate.
Spearman’s correlation analysis was utilized to quantify
the expression associations between the genes of interest.
Data are expressed as mean6 standard error of the mean
(s.e.m.). P-values less than 0!05 were considered significant.
Results
Histology
Biopsy specimens from pSS patients, but not from
nSCS subjects, were characterized by the presence of
Table 2. List of primers for reverse transcription–polymerase chain











(1 : 100 dilution)
Novus Biological, Littleton, CO, USA
Rabbit anti-human IL-22R1
(1 : 100 dilution)
Novus Biological, Littleton, CO, USA
Rabbit anti-human IL-18
(1 : 100 dilution)
Novus Biological, Littleton, CO, USA
Rabit anti-human IL-22BP
(1 : 100 dilution)
Novus Biological, Littleton, CO, USA
Mouse anti-human CD3
(1 : 100 dilution)
Dako, Glostrup, Denmark
Mouse anti-human CD68
(1 : 100 dilution)
Dako, Glostrup, Denmark
Mouse anti-human CD19
(1 : 100 dilution)
Dako, Glostrup, Denmark
Alexa FluorVR 488 Goat
Anti-Rabbit IgG
Life Technologies, Europe, BV,
Stockholm, Sweden
Alexa FluorVR 555 Goat
Anti-Mouse IgG




BD Biosciences, San Jose, CA, USA
Anti-human-CD19-FITC-
conjugated
BD Biosciences, San Jose, CA, USA
Anti-human-CD14-FITC-
conjugated
BD Biosciences, San Jose, CA, USA
Anti-human-CD68-FITC-
conjugated
BD Biosciences, San Jose, CA, USA
Anti-human-IL-22R1-PE-
conjugated
R&D Systems, Minneapolis, MN, USA
Anti-human-CD4-APC-
conjugated
BD Biosciences, San Jose, CA, USA
Anti-human-IL-17-FITC-
conjugated
R&D Systems, Minneapolis, MN, USA
APC5 allophycocyanin; FITC5 fluorescein isothiocyanate;
GAPDH 5 glyceraldehyde 3-phosphate dehydrogenase; Ig5 immuno-
globulin; PE5 phycoerythrin; STAT-35 signal transducer and activator
of transcription-3.
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periductal lymphocytic infiltration, sometimes leading
to the formation of ectopic lymphoid structures and
germinal centre-like structures, accompanied by various
degrees of atrophy or severe destruction of the acini
(not shown). An additional 10 patients with NHL, all
women affected by primary SS, were also considered.
The diagnosis of pSS was established 6–20 years before
the diagnosis of NHL. Seven cases were low-grade mar-
ginal zone B cell lymphoma with lymphoepithelial
lesions, two were nodal lymphomas and the last was a
high-grade extranodal diffuse large B cell lymphoma
involving the retroperitoneal area. The B phenotype of
each lymphoma was confirmed using the pan-B anti-
body CD20.
F. Ciccia et al.
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IL-22R1 in pSS patients
The MSG over-expression of IL-22 and IL-18 was con-
firmed by RT–PCR and immunohistochemistry (IHC) in
this new cohort of pSS patients (Supporting information,
Fig. S1a–h, respectively). In particular, IL-22 was
expressed mainly among infiltrating mononuclear cells of
pSS with no significant epithelial expression (Supporting
information, Fig. S1a–c). Conversely, IL-18 was expressed
strongly in both infiltrating mononuclear and epithelial
cells (Supporting information, Fig. S1d–f). No significant
co-expression of IL-22 and IL-18 was observed in pSS
(data not shown). We next evaluated the expression of
the inducible IL-22R1 subunit. IL-22R1 expression was
detected among infiltrating mononuclear cells (Fig. 1b–e),
endothelial cells of vessels scattered through the inflamed
salivary glands (Fig. 1e, asterisk) and acinar epithelial cells
(Fig. 1b). Conversely, only rare acinar and ductal epithe-
lial positivity was observed in the salivary glands of nSCS,
IL-22R1 being observed essentially among endothelial
cells (Fig. 1a). The percentage of infiltrating IL-22R1-
expressing cells/infiltrating mononuclear cells was corre-
lated significantly with the lymphocytic focus score (Fig.
1f) and related directly to the percentage of IL-18-
expressing cells/infiltrating mononuclear cells (Fig. 1g).
IL-22R1 m-RNA was also evaluated by RT–PCR in both
whole SGs and isolated SGMC. In pSS patients with focus
score (FS) 1 and 2 the m-RNA levels of IL-22R1 was not
significantly different from the controls (Fig. 1h,i). Con-
versely, patients with higher FS (3–4) displayed a signifi-
cant down-regulation of the mRNA levels (Fig. 1h,i)
compared to nSCS. In order to clarify which cells express
IL-22R1, double immunostaining by confocal laser scan-
ning microscopy was performed. Epithelial cells expressed
IL-22R1 (Fig. 1j), only a very small percentage of CD31
cells displayed IL-22R1 positivity (Fig. 1l) and no IL-22R1
expression was found among CD191 cells (Fig. 1m), the
majority of tissue IL-22R1-expressing cells also being
CD681 (Fig. 1k). CD681 cells were observed to infiltrate
the salivary glands of pSS patients compared significantly
with nSCS, their number being correlated strongly and
directly with the focus score (Fig. 1n–q). Finally, the func-
tionality of IL-22R1 expression on immune cells of pSS
was confirmed by the demonstration of a significant co-
localization of IL-22R1 and pSTAT-3 (Fig. 2a–d).
The expression of IL-22R1 in MSG of pSS patients was
also confirmed by flow cytometric analysis on salivary gland
isolated mononuclear cells (SGMC) and on circulating blood
mononuclear cells. As shown in Fig. 2e,f, IL-22R1 was
expressed on the surface of macrophages (54!86 14%) iso-
lated from the SGMC of pSS but not nSCS subjects. A signifi-
cant percentage of circulating monocytes (616 18%) also
expressed IL-22R1 in pSS (Fig. 2g,h), its expression being vir-
tually absent in nSCS, and in healthy controls (not shown).
IL-18 and IL-22 modulates the in-vitro expression of
IL-22R1
Because IL-22 was expressed mainly in MSG with the high-
est FS, we next evaluated whether the different modulation
of IL-22R1 observed might be related to a negative feedback
regulation. MSG-derived cells obtained from five patients
with FS 1–2 were stimulated with recombinant IL-22 and
the expression of IL-22R1 was assessed by RT–PCR. As
shown in Fig. 3a, in the presence of high concentrations of
IL-22 the m-RNA levels of IL-22R1 were reduced signifi-
cantly. Because of the role of IL-18 in modulating the IL-22
axis [10] and the correlation between IL-22R1 and IL-18
expression in pSS, we investigated whether IL-18 might also
be involved in the regulation of the IL-22 axis in salivary
glands of pSS. IL-18 stimulation significantly up-regulated
the expression of IL-22R1 m-RNA (Fig. 3b–d), but not of
IL-22 (Fig. 3c–e), in only pSS patients, and was accompa-
nied by a significant increase of the percentage of IL-22R1-
expressing cells, evaluated by flow cytometry (Fig. 3f).
IL-22BP in the MSG of pSS patients
As the functional outcome of IL-22 seems to depend upon
the levels of the soluble inhibitor IL-22BP, its expression
was next assessed. IL-22BP m-RNA was significantly over-
expressed (Fig. 4a) in pSS compared to nSCS. Interestingly,
Fig. 1. Interleukin (IL)-22R1 expression in the salivary glands of patients with primary Sj€ogren’s syndrome (pSS patients). (a–e) Representative
microphotographs showing IL-22R1 immunostainings in non-specific chronic sialoadenitis (nSCS) (a) and pSS patients (b–d). IL-22R1 aberrant
expression was observed among infiltrating inflammatory cells (b–e) and endothelial cells of microvessels distributed in the inflammatory
infiltrates (asterisk, e) in pSS. Insert in e: representative paraffin sections of salivary glands of pSS patients stained with rabbit immunoglobulins
(isotype control). (f) Correlation of IL-22R1 with the focus scores and with IL-18-expressing cells (g). Percentage of IL-22R1-expressing cells/
infiltrating mononuclear cells was correlated with the focus score of minor salivary glands of pSS and with the number of IL-18-expressing cells/
infiltrating mononuclear cells. The r2 and P (P < 0!0001)-values were determined with Spearman’s correlation coefficient. Relative m-RNA
quantification of IL-22R1 was assessed by quantitative reverse transcription–polymerase chain reaction (qRT–PCR) in salivary glands obtained
from 30 pSS and nSCS patients (h,i) and salivary gland mononuclear cells (SGMC) from 10 pSS and 10 nSCS patients. (j–m) Representative
images of confocal analysis of IL-22RA1 localization in pSS patients. (j) Merged double-staining for MNF-116 (red) and IL-22RA1 green. (k)
Merged double-staining of CD68 (red) and IL-22RA1 (green). (l) Merged double-staining of CD3 (red) and IL-22RA1 (green). (m) Merged
double-staining of CD19 (red) and IL-22RA1 (green). (n,o) Representative microphotographs showing CD68 immunostainings in pSS (n) and
non-Sj€ogren’s syndrome patients (nSS) patients (o). (p) Numbers of CD681 cells in pSS patients and controls. (q) Correlation of CD681 cells
with the focus scores. (a,b,e,n,o) Original magnification 3250; (c) original magnification 3400; (d,e,j–m) original magnification 3630.
3
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the highest levels of IL-22BP were observed in those pSS
patients displaying the lowest FS (Fig. 4a). Conversely, IL-
22BP immunoreactivity was weakly detectable in immune
cells scattered among the inflammatory infiltrate, being
observable only in few mononuclear cells distributed in
the proximity of ducts (Fig. 4b–d) and among ductal epi-
thelial cells (Fig. 4d). No expression of IL-22BP was
observed in nSCS MSG (Fig. 4e).
Effect of in-vitro stimulation of PBMC and SGMC
of pSS patients with IL-22
We next investigated the role of recombinant IL-22
(rIL22) in the expansion of Th17 cells in vitro stimulation
on PBMC and SGMC isolated from five pSS and fice
nSCS patients. rIL-22 induced a significant expansion of
Th17 cells (from 0!766 0!13 to 66 2!4, P < 0!05) (Fig.
5a) only in pSS, and was accompanied by the significant
up-regulation of IL-22, IL-17, RORc and STAT-3 m-RNA
levels (Fig. 5b–e).
IL 18/IL-22 axis in pSS-associated non-Hodgkin’s
lymphoma
As the IL-22/IL-22R1 axis is implicated in the pathogenesis of
B and T cells lymphomas with IL-22R1 expressed aberrantly
on the surface of neoplastic cells [13,14], we next evaluated
the expression of IL-18 and IL-22 pathways on patients with
pSS who developed non-Hodgkin’s lymphoma. A similar
expression of IL-22 (Fig. 6a,b) was observed in the mucosa-
associated lymphoid tissue (MALT) lymphoma tissues of pSS
patients compared to MSG of pSS. IL-22R1 (Fig. 6c–e) was
over-expressed in the lymphoma tissues of pSS patients,
mainly on the surface of B cells and tissue macrophages
(Supporting information, Fig. S2d–i), and was accompanied
by significant pSTAT-3 increased expression (Fig. 6f,g).
Because the activated STAT-3 promotes cell proliferation and
survival in B cell lymphomas [15] we next evaluated whether
IL-22R1-expressing cells also co-express pSTAT-3. As shown
in Fig. 6, pSTAT-3 and IL-22R1 strongly co-localize. The pro-
cancerogenic activity of IL-22 in a murine model of colon
cancer has been related to the reduced levels of its natural
inhibitor IL-22BP [10]. IL-22BP-expressing cells were
increased compared to pSS (Fig. 6l) and located exclusively in
the context of lymphoepithelial lesions and virtually absent in
the remaining the tissue specimens (Fig. 6 i–k). Concerning
the role of IL-18 in modulating the IL-22 axis in pSS patients,
we next evaluated the expression of IL-18 and the relation-
ship between IL-18 and IL-22 in pSS-associated non-Hodg-
kin lymphoma. IL-18 was expressed significantly in MALT
lymphoma tissues of pSS at levels similar to pSS, particularly
in the context of myoepithelial lesions (MESA) and in
inflammatory mononuclear cells scattered throughout the
neoplastic tissues (Fig. 6m–o), being correlated directly with
the percentage of IL-22- and IL-22R1-positive cells/infiltrat-
ing cells (r25 0!45 and r25 0!56, respectively, P< 0!05).
Conversely, IL-18-positive cells were never observed in the
Fig. 2. Interleukin (IL)-22R1 and p-signal
transducer and activator of transcription-3 (pSTAT-
3) in salivary glands and IL-22R1 expression on
isolated mononuclear cells from salivary gland
mononuclear cells (SGMC) and peripheral blood
mononuclear cells (PBMC) of primary Sj€ogren’s
syndrome (pSS) and non-Sj€ogren’s syndrome
patients (nSS) subjects. (a–d) Representative images
of confocal analysis of IL-22R1 and pSTAT-3 co-
localization in pSS patients. (a) Single-staining for
IL-22RA1 and pSTAT-3 (b). (c) Merged double-
staining of IL-22R1 (red) and pSTAT-3 (green). (d)
Merged double-staining of IL-22R1 and pSTAT-3
with 4’,6-diamidino-2-phenylindole (DAPI). (e)
Representative dot-plot of IL-22R1 expression
among SGMC from patients and controls. (f)
Percentages of IL-22R1-expressing cells among SG
CD681, CD31 and CD191 cells. (g) Representative
dot-plot of IL-22R1 expression among peripheral
blood mononuclear cells (PBMCs) from patients
and controls. (h) Percentages of IL-22R1-expressing
cells among SG CD681, CD31 and CD191 cells.
IL-22R1 expression was observed strongly in
circulating monocytes and tissue macrophages only
in pSS patients.
F. Ciccia et al.
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context of lymphoepithelial lesions and in particular in the
areas of IL-22BP expression.
Discussion
In this study we confirmed, in a new cohort of patients,
the increased expression levels of IL-18 and IL-22 and
provided the first evidence, to our knowledge, that (i) in
pSS IL-22R1 is expressed aberrantly on haematopoietic
cells at both systemic and salivary gland level; (ii) there is
a tissue deficit in the expression of the natural inhibitor
of IL-22, IL-22BP and (iii) the IL-22 axis seems to be
functionally dependent upon IL-18 signalling. We also
demonstrated that IL-18 and IL-22/IL-22R1 but not IL-
22BP are over-expressed in the non-Hodgkin lymphoma
tissues of pSS patients.
Primary Sj€ogren’s syndrome is a chronic autoimmune
disease characterized by altered cytokine networks [1,5],
with IL-22 over-expressed in the serum and salivary glands
of pSS patients and correlated with hyposalivation, the
presence of autoantibodies and the lymphocytic focus score
[5,16]. IL-22 is a member of the IL-10 family of proteins
whose functional outcome depends upon the presence of
the balance between the inducible IL-22R1 subunit and the
levels of IL-22 binding protein (IL-22BP) [6]. In the salivary
glands of pSS, we observed a relative imbalance of IL-22/IL-
22BP because the strong amount of IL-22 in the context of
inflammatory infiltrate was not accompanied by a concom-
itant expression of IL-22BP. IL-22BP immunoreactivity
was, in fact, observed predominantly in the ducts lumen of
pSS, suggesting its predominant epithelial production and
lumen secretion, while IL-22 positivity among mononu-
clear cells correlated inversely with that of IL-18. The level
of IL-22BP seems to be controlled by IL-18 [10], a cytokine
that belongs to the IL-1 superfamily [8] and that synergiz-
ing with IL-12 and IL-23 also enhances IL-22 levels in Th1
and gd T cells, respectively [9]. IL-18 is released as an
immature form and then processed into its mature forms
through the activation of the NLRP3 inflammasome via the
purinergic P2X7 receptor [8]. In pSS, both IL-18 and
P2X7R are over-expressed and correlated with local and
systemic clinical indicators of the degree of the disease
[4,17], suggesting a direct role of the P2X7R–inflamma-
some complex and of IL-18 in the pathogenesis of pSS.
Here we speculate that increased IL-18 expression,
observed in the MSG of pSS, may be implicated in the
dysfunctional behaviour of the IL-22 axis. IL-18 was corre-
lated significantly with the expression level of IL-22 and
IL-22R1 in the inflammatory infiltrates of pSS patients.
Furthermore, IL-18 stimulation seems to be sufficient to
up-regulate IL-22R1 significantly on PBMCs of pSS, with-
out apparent effect on IL-22 levels; this is related possibly
to the absence, in our in-vitro experiments, of other proin-
flammatory cytokines required for the expression of IL-22
in immune cells. IL-18 has been demonstrated previously
to reduce the levels of IL-22BP in isolated PBMC of nor-
mal subjects [9]. In our study, an inverse distribution was
found between IL-18 and IL-22BP in MSG of pSS patients,
apparently confirming the important role of IL-18 in also
negatively modulating the IL-22BP behaviour in pSS.
Fig. 3. Effect of recombinant interleukin (IL)-22
on salivary gland mononuclear cells (SGMCs)
and IL-18 on peripheral blood mononuclear cells
(PBMCs) of primary Sj€ogren’s syndrome (pSS).
(a) IL-22R1 mRNA expression was down-
regulated after incubation of SGMCs with
recombinant IL-22. PBMCs from 10 pSS and 10
non-specific chronic sialoadenitis (nSCS) subjects
were isolated and cultured with 10 and 20 ng/ml
of recombinant IL-18. The percentage of
IL-22R1-expressing cells and the m-RNA
expression levels of IL-22R1 and IL-22 were
assessed by flow cytometry and reverse
transcription–polymerase chain reaction
(RT–PCR). (b,c) Relative m-RNA quantification
of IL-22R1 (b) and IL-22 (c) was assessed in
isolated PBMCs from non-Sj€ogren’s syndrome
patients (nSS) before and after incubation with
recombinant IL-18. (d,e) Relative m-RNA
quantification of IL-22R1 (d) and IL-22 (e) was
assessed in isolated PBMCs from pSS before and
after incubation with recombinant IL-18. (f)
representative dot-plot showing percentages of
IL-22R1-expressing cells before and after
exposure to recombinant IL-18. *P5 0!00013.
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The suggested IL-18-dependent increased expression of
IL-22R1 might be relevant in the pathogenesis of pSS. IL-
22R1 expression has been demonstrated to be restricted,
in physiological conditions, only to non-haematopoietic
cells [6]. Using immunohistochemistry and flow cytome-
try, we were able to demonstrate that IL-22R1 aberrant
expression occurs on haematopoietic cells of pSS patients
at both local and systemic levels and that IL-18 signifi-
cantly modulated the expression of IL-22R1 on these
cells. Over-expression of IL-22R1 in the SG seems to be
specific to pSS and not related to the presence of a signif-
icantly higher proportion of macrophages compared to
controls. Using RT–PCR, however, we observed a differ-
ent regulation of its expression. In patients with lower FS,
IL-22R1 expression was not different compared to con-
trols, being down-regulated significantly in those with
higher FS. This finding was surprising, as the strong pro-
tein expression of IL-22R1 was confirmed analysing the
whole SG rather than the isolated SGMC of pSS. Dissoci-
ation of messenger RNA and protein expression in
Fig. 4. Interleukin (IL)-22BP expression in the salivary glands of patients with primary Sj€ogren’s syndrome (pSS patients). Relative m-RNA
quantification of IL-22BP (a) was assessed by quantitative reverse transcription–polymerase chain reaction (qRT–PCR) in salivary glands
obtained from 30 pSS patients and non-Sj€ogren’s syndrome patients (nSS). (b–d) Representative microphotographs showing IL-22BP
immunostainings in pSS (b–d) and nSS (e) subjects. IL-22BP expression was weakly observed among infiltrating mononuclear cells scattering in
the inflammatory infiltrates, being observable only in few mononuclear cells distributed in the proximity of ducts (d, arrows). A clear IL-22BP
expression was observed in ductal epithelial cells and in the lumen ducts (b–d). (e) No significant IL-22BP immunoreactive cells were observed
in nSS subjects. (f) Representative paraffin sections of salivary glands of pSS patients stained with rabbit immunoglobulins (isotype control).
(b) Original magnification 3100; (c–f) Original magnification 3250.
Fig. 5. Effect of recombinant interleukin (IL)-22
on peripheral blood mononuclear cells (PBMCs)
of pSS. PBMCs from 10 primary Sj€ogren’s
syndrome (pSS) patients were isolated and
cultured with 0!1 ng/ml of recombinant IL-22.
The percentage of IL-17-expressing cells and the
m-RNA expression levels of IL-17, IL-22,
IL-22R1, signal transducer and activator of
transcription-3 (STAT-3) and RAR-related
orphan receptor (ROR)c were assessed by flow
cytometry and reverse transcription–polymerase
chain reaction (RT–PCR). (a) Representative dot
plot showing the percentage of IL-17 expressing
cells before and after exposure to recombinant
IL-22. (b–e) Relative m-RNA quantification of
IL-17 (b), IL-22 (c), STAT-3 (d) and RORc (e)
was assessed in isolated PBMCs from pSS before
and after incubation with recombinant IL-22.
*P< 0!05.
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human lymphoid tissues has been demonstrated previ-
ously [18], and the contrasting behaviour of IL-22R1 pro-
tein and RNA in pSS tissues may suggest that
translational and post-translational control mechanisms
play a significant role in regulating IL-22R1 levels. We
could not exclude, however, the occurrence of a counter-
regulation mechanism due to the excessive IL-22/IL-22R1
interaction, as demonstrated by the significant reduction
of IL-22R1 mRNA levels we observed in SGMCs cultured
in the presence of increasing amounts of IL-22. High
infiltration levels of macrophages has been shown in the
autoimmune lesions of pSS with lymphoma [19] and, in
our study, macrophages located in close proximity to
CD201 cells were the main cells expressing IL-22R1. As
IL-22 seems to be involved in the germinal centre forma-
tion, probably by driving and maintaining CXCL13 pro-
duction [20], IL-22R1-expressing macrophages could
participate strategically in the organization of immune
response in pSS. Interestingly, the abnormal expression of
IL-22R1 on haematopoietic cells was accompanied by a
concomitant expression of pSTAT-3 suggesting strongly,
in our opinion, the existence of an autocrine IL-22 stimu-
latory loop in pSS. Notably, IL-22R1 aberrant expression
was also observed on peripheral monocytes and, to a
lesser extent, on T lymphocytes from pSS patients. Con-
versely, IL-22R1 was never expressed on the surface of
immune cells of PBMC isolated from NSCS patients and
normal controls. Taken together, these results seem to
suggest that IL-22R1 aberrant expression at both local
and systemic level is a specific feature of pSS patients.
In the present study, we also examined the immuno-
logical consequences of the atypical expression of IL-22R1
in pSS. In-vitro stimulation of PBMCs with IL-22 only in
pSS resulted in a significant up-regulation of the m-RNA
levels of IL-17, IL-22, ROR-c and STAT-3, accompanied
by a significant expansion of IL-17-producing CD3-
expressing cells. These results are in agreement with those
obtained in previously published studies that analysed
patients with ALK1 anaplastic large cell lymphoma
(ALCL) and IL-22R1 transgenic mice [13,21]. Patients
with ALK1ALCL, who abnormally express the IL-22R1
on lymphomatous T cells, immunologically display
increased serum levels of IL-22 and IL-17 [13]. Similarly,
IL-22R1 transgenic animals that express IL-22R1 on lym-
phocytes develop a systemic inflammatory disease charac-
terized by increased levels of circulating IL-17,
granulocyte colony-stimulating factor and IL-22 [21].
Taken together, these findings suggest that the atypical
expression of IL-22R1 on haematopoietic cells generates a
strong IL-22-polarized immune response in a positive
autoregulatory loop. The differential IL-22R1 expression
observed in NSCS patients and controls highlights, in our
opinion, the importance of a tightly regulated IL-22R1
expression on immune cells in preventing systemic
inflammatory reactions. In physiological conditions, IL-22
acts as a proinammatory cytokine but only on epithelial
linings of mucosal barriers (the only cells expressing IL-
22R1) to defend rapidly against pathogens [7].
Sj€ogren’s syndrome is associated with highly increased
risk factors for the development of salivary gland lym-
phoma [2]. The IL-22/IL-22R1/STAT-3 axis has been dem-
onstrated previously to play a pivotal role in human
tumorigenesis, with IL-22R1 being expressed aberrantly on
the surface of B and T lymphomatous cells [13,14,22–25].
Fig. 6. Interleukin (IL)-22R1 p-signal transducer
and activator of transcription-3 (pSTAT-3) and
IL-18 expression in non-Hodgkin lymphomas
(NHL) of primary Sj€ogren’s syndrome (pSS)
patients. (a,b) Representative microphotographs
showing IL-22 (a), IL-22R1 (c–d), pSTAT-3 (e),
IL-22BP (i–k) and IL-18 (m–o) immunostainings
in NHL of pSS patients. Intense immunostainings
of IL-22 (a,b) and IL-22RA1 (c–e) was observed
in NHL tissues of pSS and was accompanied by
the intense expression of pSTAT-3 (e,f). (h)
Representative images of confocal analysis of
IL-22RA1 and pSTAT-3 co-localization in NHL
tissues of pSS patients. i–k: IL-22BP was
expressed only in the context of lymphoepithelial
lesions in NHL tissues. l: quantification of
IL-22BP1 cells. (m–o) IL-18 expression was
weakly observed among lymphoepithelial lesions
(m) but expressed strongly in the context of
myoepithelial lesion (n) and in the neoplastic
tissues (o). P5 quantification of IL-181 cells a,
c–d, h, i–k and m–o5 original magnification
3250; (e) original magnification 3630.
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Interestingly, it seems that the balance between IL-22 and
its soluble antagonist IL-22BP, more than the expression of
IL-22 per se, critically regulates tumorigenesis [10].
Although the comparison between MSGs and parotid gland
expression of cytokine and cytokine receptor might not,
necessarily, be biologically significant, in our study IL-22
was expressed consistently in the lymphoma tissues of pSS
patients and was accompanied by an aberrant IL-22R1
over-expression on lymphoma-infiltrating cells. The abnor-
mal IL-22R1 expression was also associated with the co-
expression of pSTAT-3, suggesting that a persistent IL-22
stimulation may be of biological importance in the growth
of non-Hodgkin lymphoma. Furthermore, activation of IL-
22 pathway seemed to be not counter-balanced sufficiently
by a parallel increased expression of IL-22BP, as the latter
was localized exclusively in correspondence of lymphoepi-
thelial lesions, and virtually absent in the remaining parts
of the neoplastic tissue. Interestingly, the IL-22 axis activa-
tion in lymphoma tissues of pSS was correlated directly and
strongly with IL-18. Tissue expression of IL-18 has been
suggested to be a histopathological indicator of the risk of
lymphomagenesis in pSS being correlated with the occur-
rence of clinical and serological indicators of a high risk of
B cell lymphoma, such as persistent C4 hypocomplemen-
taemia and salivary gland enlargement [26]. Although IL-
18 cannot be considered a direct causative agent of lym-
phoma in pSS, our observation of the mutually exclusive
distribution of IL-18 and IL-22BP in lymphoma tissues
may be relevant, IL-22BP being absent when IL-18 was
present and vice versa.
In conclusion, we have provided evidence of an imbal-
ance between IL-22 and IL-22BP and of the aberrant
expression of IL-22R1 in MSG and PBMC of pSS
patients, also providing demonstration of the IL-22R1
functional relevance. We have also demonstrated that spe-
cific aberrant activation, IL-18-driven, of the IL-22R1/
STAT-3 pathway occurs in the inflamed salivary glands
and NHL lymphoma of pSS patients. Blocking the aber-
rant IL-18/IL-22 pathway may be a useful therapeutic
strategy for pSS and pSS-associated lymphomas.
Disclosure
The authors declare no financial conflicts of interest.
Acknowledgements
We thank Dr Francesca Raiata for her technical support in
the immunohistochemical experiments. This work was sup-
ported in part by a grant from the Ministry of the University
and Scientific Research of Italy.
References
1 Roescher N, Tak PP, Illei GG. Cytokines in Sjogren’s syndrome:
potential therapeutic targets. Ann Rheum Dis 2010; 69:945–8.
2 Dias C, Isenberg DA. Susceptibility of patients with rheumatic
diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol
2011; 7:360–8.
3 Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren’s syndrome
and malignancy risk: a systematic review and meta-analysis.
Ann Rheum Dis 2014; 73:1151–6.
4 Bombardieri M, Barone F, Pittoni V et al. Increased circulat-
ing levels and salivary gland expression of interleukin-18 in
patients with Sj€ogren’s syndrome: relationship with autoanti-
body production and lymphoid organization of the periduc-
tal inflammatory infiltrate. Arthritis Res Ther 2004; 6:
R447–56.
5 Ciccia F, Guggino G, Rizzo A et al. Potential involvement of IL-
22 and IL-22-producing cells in the inflamed salivary glands of
patients with Sjogren’s syndrome. Ann Rheum Dis 2012; 71:
295–301.
6 Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17
cytokine. Immunol Rev 2013; 252:116–32.
7 Lin C, Savan R. The role of the IL-22/IL-22R1 axis in cancer.
Cytokine Growth Factor Rev 2014; 25:257–71.
8 Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18
and IL-18 binding protein. Front Immunol 2013; 4:289.
9 Gurney AL. IL-22, a Th1 cytokine that targets the pancreas and
select other peripheral tissues. Int Immunopharmacol 2004; 4:
669–77.
10 Huber S, Gagliani N, Zenewicz LA et al. IL-22BP is regulated by
the inflammasome and modulates tumorigenesis in the intes-
tine. Nature 2012; 491:259–63.
11 Vitali C, Bombardieri S, Jonsson R et al. Classification criteria
for Sj€ogren’s syndrome: a revised version of the European crite-
ria proposed by the American–European Consensus Group.
Ann Rheum Dis 2002; 61:554–8.
12 Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopa-
thology of Sjogren’s syndrome in labial salivary gland biopsies.
Oral Surg Oral Med Oral Pathol 1974; 37:217–29.
13 Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant
expression of IL-22 receptor 1 and autocrine IL-22 stimulation
contribute to tumorigenicity in ALK1 anaplastic large cell lym-
phoma. Leukemia 2008; 22:1595–603.
14 Gelebart P, Zak Z, Dien-Bard J, Anand M, Lai R. Interleukin 22
signaling promotes cell growth in mantle cell lymphoma. Transl
Oncol 2011; 4:9–19.
15 Ding BB, Yu JJ, Yu RY et al. Constitutively activated STAT3 pro-
motes cell proliferation and survival in the activated B-cell
subtype of diffuse large B-cell lymphomas. Blood 2008; 111:
1515–23.
16 Lavoie TN, Stewart CM, Berg KM, Li Y, Nguyen CQ.
Expression of interleukin-22 in Sj€ogren’s syndrome: significant
correlation with disease parameters. Scand J Immunol 2011;
74:377–82.
17 Baldini C, Rossi C, Ferro F et al. The P2X7 receptor-
inflammasome complex has a role in modulating the inflamma-
tory response in primary Sj€ogren’s syndrome. J Intern Med
2013; 274:480–9.
18 Chleq-Deschamps CM, LeBrun DP, Huie P et al. Topographical
dissociation of BCL-2 messenger RNA and protein expression in
human lymphoid tissues. Blood 1993; 81:293–8.
19 Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM.
Characteristics of the minor salivary gland infiltrates in
Sj€ogren’s syndrome. J Autoimmun 2010; 34:400–7.
F. Ciccia et al.
228 VC 2015 British Society for Immunology, Clinical & Experimental Immunology, 181: 219–229
20 Khader SA, Guglani L, Rangel-Moreno J et al. IL-23 is required
for long-term control of Mycobacterium tuberculosis and B cell
follicle formation in the infected lung. J Immunol 2011; 187:
5402–7.
21 Savan R, McFarland AP, Reynolds DA et al. A novel role for IL-
22R1 as a driver of inflammation. Blood 2011; 117:575–84.
22 Ye ZJ, Zhou Q, Yin W et al. Interleukin 22-producing CD41 T
cells in malignant pleural effusion. Cancer Lett 2012; 326:23–32.
23 Curd LM, Favors SE, Gregg RK. Pro-tumour activity of
interleukin-22 in HPAFII human pancreatic cancer cells. Clin
Exp Immunol 2012; 168:192–9.
24 Miyagaki T, Sugaya M, Suga H et al. IL-22, but not IL-17, dom-
inant environment in cutaneous T-cell lymphoma. Clin Cancer
Res 2011; 17:7529–38.
25 Jiang R, Tan Z, Deng L et al. Interleukin-22 promotes human
hepatocellular carcinoma by activation of STAT3. Hepatology
2011; 54:900–9.
26 Manoussakis MN, Boiu S, Korkolopoulou P et al. Rates of infil-
tration by macrophages and dendritic cells and expression of
interleukin-18 and interleukin-12 in the chronic inflammatory
lesions of Sj€ogren’s syndrome: correlation with certain features
of immune hyperactivity and factors associated with high risk
of lymphoma development. Arthritis Rheum 2007; 56:3977–88.
Supporting information
Additional Supporting Information may be found in the
online version of this article.
Fig. S1. Interleukin (IL)-18 and IL-22 expression in pri-
mary Sj€ogren’s syndrome (pSS) and non-specific chronic
sialoadenitis (nSCS) patients. (a–c) Representative micro-
photographs showing IL-22 immunostainings in nSCS (a)
and pSS (b,c) patients. (d–f) Representative microphoto-
graphs showing IL-18 immunostainings in nSCS (d) and
pSS (e,f) patients. (g,h) Relative m-RNA quantification of
IL-22 (g) and IL-18 (h) was assessed by quantitative
reverse transcription–polymerase chain reaction (qRT–
PCR) in salivary glands obtained from 30 pSS and nSCS
patients. (a–f) Original magnification 3250.
Fig. S2. Interleukin (IL)-22R1 expressing cells in mucosa-
associated lymphoid tissue (MALT) lymphoma tissues of pri-
mary Sj€ogren’s syndrome (pSS) patients. (a–c) Representative
images of confocal analysis of IL-22R1 and CD3 co-
localization in MALT tissues. (a,b) Single-staining for IL-
22RA1 (a) and CD3 (b). (c) Merged double-staining of CD3
(red) and IL-22RA1 (green). (d–f) Representative images of
confocal analysis of IL-22R1 and CD19 co-localization in
MALT tissues. (d,e) Single-staining for IL-22RA1 (d) and CD3
(e). (f) Merged double-staining of CD19 (red) and IL-22RA1
(green). (g–i) Representative images of confocal analysis of IL-
22R1 and CD68 co-localization in MALT tissues. (g,h) Single-
staining for IL-22RA1 (g) and CD68 (h). (i) Merged double-
staining of CD68 (red) and IL-22RA1 (green). (a–i) Original
magnification3250.
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